Back to "Meet our senior experts" overview
Chris Watts is a partner within the consulting group in NNE Pharmaplan and heads the company's quality and regulatory group in North America.
Chris holds a Doctorate in pharmaceutical science from the University of Tennessee, and a Baccalaureate in biomedical engineering from Boston University.
He recently joined NNE Pharmaplan from the FDA, where he was part of the team developing policies and systems for the agency’s science and risk-based approach to cGMP inspection and CMC application review, including the recent guidance on process validation. Prior to the FDA, Chris was responsible for the development and manufacture of NCE (new chemical entity) and biotech products at Dura Pharmaceuticals and Shire Laboratories.
Chris has been engaged in several quality and regulatory projects, from developing risk-based approaches for product and process development, to strategies and systems for quality management.
You can contact Chris on: +1 919 809 3216
View Chris' LinkedIn profile
Chris' upcoming event
The list below shows upcoming events at which Chris is speaking or engaged in otherwise.
| Event: |
57th annual analysis division synposium |
| Description: |
Chris will give a presentation regarding the integration of analysers in automation systems |
| When: |
25 April |
| Where: |
Anaheim/California, USA |
| |
|
Articles by Chris Watts
| Title: |
Risk analysis and mitigation matrix (RAMM) - a risk tool for quality management |
| Co-authors: |
Alex Brindle, Steve Davy and David Tiffany |
| Journal: |
Pharmaceutical Engineering |
| Year of publication: |
2012 |
| |
|
Back to "Meet our senior experts" overview